Objective: To investigate the current prescribing practices in the treatment of depression and to determine to whether these practices reflect research findings.
INTRODUCTION
The past decade has seen an increase in the number and type of antidepressants available to psychiatrists and other clinicians. In Trinidad and Tobago there are at least 14 antidepressants available. It is important to better understand current prescribing practices and to what degree these practices reflect research findings.
Recent information suggests that psychiatrists chose antidepressants with more tolerable side effects 1 a decreased risk of harm in overdose, and better treatment efficacy 2 .
Numerous factors influence choosing an antidepressant drug therapy 3 . The extent of influence of evidence-based medicine on physicians' practice and prescribing habits has been questioned 4 , 5 .
Less than a decade ago, studies on drug choice in Europe revealed that the tricyclic antidepressant (TCA) amitriptyline was the first-line treatment choice for most psychiatrists 6 , 7 . Huszonek and others described the trend of US retail pharmacy prescriptions by psychiatrists between 1986 and 1989, before and after the introduction of fluoxetine 1 A previous study done in Trinidad by Moore and others 12 in1998/99 found that the TCAs, mainly amitryptiline, were the antidepressants most prescribed in outpatients psychiatric clinics in Trinidad and fluoxetine was the only selective serotonin reuptake inhibitor (SSRI) prescribed in these clinics.
The purpose of this study was to examine current prescribing practices of all practicing psychiatrists, psychiatric residents in postgraduate training and clinicians working in the psychiatric services for over five years in Trinidad and Tobago and to determine to what degree these practices reflect research findings. 
METHOD

RESULTS
Of the thirty-six questionnaires sent, there were 31 respondents, an overall response rate of 86%. Two respondents, both male psychiatrists, were excluded from the study. One indicated that he was in administration and had not prescribed medication for over five years and the other had not been actively practicing at the time of the study. The mean age of the respondents could not be calculated, as 52% (15/29) respondents did not state their age. Sixty-two % (18/29) were male and %(11/29) female. The respondents were 15 (52%) psychiatrists, 8 (28%) psychiatrists in training in the University of the West Indies D.M. postgraduate program in psychiatry and 6 (21%) doctors were neither psychiatrists nor psychiatrists in training, but were working in the psychiatric services for more than 5 years. The majority 55%(16/29) worked in a public outpatient and institutional setting, 42% (12/29) worked in a combined private-practice setting and a public outpatient and institutional setting, and 3% (1/29) was solely in private practice. The characteristics of nonresponders were not obtained.
The SSRIs were prescribed most frequently 15/29 (72%) in the treatment of a newly case of major depression followed by the SNRIs in 17% (5/29) ( Table 1) . Of the SSRIs, fluoxetine 52% (15/29) and paroxetine 24% (7/29) were favoured ( Table 2) . Eighty-six percent (25/29) indicated that the tricyclic that they used most frequently in the treatment of depression was amitryptiline (Table 3) . Seven percent (2/29) indicated that they used the reversible MAOI, moclobemide, in the treatment of depression and 93% (27/29) did not use MAOIs (Table 4 ). (Table 5) . Seventy-nine percent (23/29) indicated that the SSRI group of antidepressants had the least side effects (Table 6 ). Seventy-six percent (22/29) indicated that the tricyclic group of antidepressants had the most side effects (Table 7) . Sixty-two percent (18/29) indicated that amitryptiline was the antidepressant most likely to cause weight gain (Table 8 ). Fluoxetine was endorsed as most likely to be associated with sexual dysfunction 55% (16/29), a discontinuation syndrome 35% (10/29), agitation 52% (15/29) and insomnia 55% (15/29). (Table 26 ), 52% (15/29) also indicated that they would prescribe an SSRI for anxiety with depression (Table  27 ), 93% (27/29) indicated that they would prescribe an SSRI for panic disorder with depression (Table 28) , 52% (15/29) indicated that they would prescribe SSRI for depression with suicidal ideation (Table 29) , 24% (7/29) indicated that they would prescribe an SSRI for atypical depression (Table 30 ) and 59% (17/29) indicated that they would prescribe the TCA, amitryptiline for depression with prominent insomnia (Table 31 ). (Table 33) . Eighty-three percent (24/29) respondents saw patients at least once every two weeks in the first month of treatment of an episode of depression (Table 35) . Clinicians reported using between 1 to twelve antidepressants each. Thirty-eight percent (11/29) of respondents never used ECT and 24% (7/29) had not used ECT for more than five years. Only 10%(3/39) used ECT within the past year.
DISCUSSION
The survey reflected the prescribing pattern for the period studied September 1 to November 30 2002. The data is similar to those of Petersen et al 13 and Olfson and others 8 in both the choice of specific antidepressant agents and the preference for the class of SSRIs (72%) and SNRIs (17%) over the TCAs (7%). According to this study, SSRI agents are favoured as first line treatment in a first episode of depression and are prescribed more frequently than TCA agents. The SSRIs were probably the drug class of choice because the side effects are better tolerated than the older drugs, there is better patient compliance with the once a day dosing and the suicide potential is low. This finding is, however, inconsistent with those of a 2002 study by Moore and others 12 who found that TCAs, mainly amitryptiline, were the antidepressants most prescribed in outpatients psychiatric clinics in Trinidad and fluoxetine was the only selective serotonin reuptake inhibitor (SSRI) prescribed in these clinics. The discrepancy in these findings might be explained by the fact that the study by Moore and others 12 was done between 1998 and 1999 when fluoxetine was the only SSRI available in public outpatient clinics. This situation has since changed and the SSRIs, paroxetine and sertraline, were available at these clinics at the time this study was being done.
Although recent meta-analyses failed to find clinically important differences in efficacy between SSRIs and tricyclic antidepressants 14 , 15 , 16 and all antidepressants are believed to be equally efficacious for the treatment of depression 17 , 55%(16/29) clinicians indicated a belief that SSRIs were most efficacious, 14% (4/29) indicated that the SNRI, venlafaxine was most efficacious and 14% (4/29) indicated that antidepressants were equally efficacious. Despite the lack of evidence of a significant difference in efficacy between older and newer agents, the majority of clinicians perceived the newer agents to be more efficacious than the older TCAs and monoamine oxidase inhibitors (MAOIs).
In general, there was a trend for respondents to prescribe the lowest recommended dosage of SSRIs, SNRIs, tricyclics and other antidepressants.
Respondents were using between 1 and 12 antidepressants each. Although the majority of respondents felt that the SSRIs were the most efficacious group of drug with the least side effects and 76% (22/29) indicated that the tricyclics caused most side effects, 93% (27/29) were currently prescribing amitryptiline. Additionally, although sexual dysfunction and agitation appear to occur at similar rates with all the SSRIs , fluoxetine was perceived to be most likely to cause these side effects.
Most respondents based their choice of antidepressant on factors such as previous response to treatment, presence of comorbid medical conditions, side effect profile, cost, age and availability of samples.
Despite inadequate evidence to support the efficacy of combining antidepressants and significant risks of drug-drug interactions leading to delayed metabolism and potentially dangerous serum levels (e.g. SSRIs + TCAs) 18 , 19 , 24% (7/29) respondents indicated that they combined SSRIs and TCAs and 3% (1/29) combined SSRIs and bupropion.
The majority of respondents stated that they would prescribe TCAs for depression with prominent insomnia. For all other types of depression (major depression with fatigue, anxious depression, panic disorder with depression with suicidal ideation and atypical depression) SSRIs were deemed to be the class of drugs that would most likely be prescribed.
Most clinicians were treating a first episode of depression for an adequate period of six months or more and 38% (11/29) had never used electroconvulsive therapy in the treatment of depression.
The limitations of the study: 1. The opinions surveyed were subjective, and this limits attempts to understand this complex problem. 2. The response rate was not 100%.
CONCLUSIONS
At the time this study was conducted, the newer antidepressants, the SSRIs and the SNRIs were prescribed in the majority of cases and were considered to be of greater efficacy than the older antidepressants such as the TCAs and MAOIs. They were probably favored because their use was associated with fewer side effects and better patient compliance. Several factors, including previous response to treatment, influenced prescribing habits. Doctors in the psychiatric services were prescribing recommended dosages of antidepressants for an adequate time period.
These findings are significant as they highlight the discrepancy between empirical evidence and clinical practices and suggest that other factors influence clinicians' medication choices in the treatment of depression.
